$BWIN

Baldwin (BWIN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Executive Director of Investor Relations - Bonnie Bishop Chief Executive Officer - Trevor Lowry Baldwin Chief Financial Officer - Bradford Lenzie Hale TAKEAWAYS Revenue -- $493 million, representing 2% total organic revenue growth during the period. Adjusted EBITDA -- $117 million, compared to $86 million in the prior-year period.

Original reporting
Published Jul 31, 2026, 3:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Baldwin (BWIN) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$BWINBullishMed
01

Why it matters

Traders can update models using the provided Q3 guidance ranges (revenue, adjusted EBITDA, adjusted EPS) and assess risk from IAS retention headwinds and soft property pricing affecting Juniper Re.

02

Market read

The call is a direct guidance and capital allocation update, with margin and FCF improvement but also explicit retention and soft-market headwinds.

03

What to watch

Leverage is at the top end of the communicated range (4.5x), and management says it cannot buy shares currently, which may reduce near-term shareholder-return support even with a completed buyback tranche.

Relevance 8/10Novelty 8/10Timing: pre-market positioning for Q3 expectations, guidance ranges and buyback/leverage context

Background

Baldwin’s Q2 2026 call covers segment organic growth, margin/FCF drivers, AI transformation progress, and provides Q3 and full-year 2026 guidance.

Company-level read

Ticker impact

$BWINBullishMedium confidence
Context

Baldwin reported Q2 results and issued Q3 2026 revenue, EBITDA, and EPS guidance, plus a $80M buyback and 4.5x leverage update.

Expected impact

Moderate upside bias if investors buy into mid-single-digit organic growth and margin expansion, but leverage at the top end may cap multiple expansion.

Evidence & confidence

The article provides concrete Q2 prints (revenue, adjusted EBITDA/EPS, FCF) and explicit Q3 guidance ranges, plus a stated leverage profile (4.5x) that limits additional buybacks. These are actionable inputs for earnings-model and positioning decisions.

Market effects

Highlights ongoing insurance brokerage and MGA/TPA growth resilience despite soft property pricing, which can influence read-across for specialty insurance intermediaries.

No specific regional market catalyst beyond US-listed company guidance.

Limited, as the disclosures are company-specific and tied to US segments and guidance.

Counterpoint

Retention headwinds (IAS) and Juniper Re risk-adjusted rate declines suggest the growth narrative may be more mix-driven than demand-driven, increasing downside risk to organic growth assumptions.

Key entities

  • Baldwin Insurance Group

    Reported Q2 2026 results and guided Q3 2026 revenue, adjusted EBITDA, and adjusted EPS, while discussing leverage and buyback capacity.

  • CAC Group

    Integration update with CAC revenue growth and new business wins cited as outperforming cross-sell and synergy targets.

  • Brev

    Inaugural reciprocal exchange now licensed in 13 states, with migration beyond Texas underway.

Related articles

$BWINMedAI 8/10

CAC acquisition drives Baldwin's 30% revenue jump in Q2

Baldwin reported Q2 2026 commissions and fees of $488.8 million, up 30% from $376.2 million a year earlier, driven largely by its January 2026 CAC Group acquisition. Organic revenue growth was 2% (vs 11% in Q2 2025). IAS organic growth was -2%, while UCTS grew 6% and MIS grew 4%. GAAP net loss was $56 million. Q3 revenue guidance is $485–$495 million with mid-single-digit organic growth.

$BWINMed

Baldwin Insurance Group, Inc. (BWIN): Results of Operations and Financial Condition

Baldwin Insurance Group, Inc. (BWIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1fy2026q2earningsrele.htm EX-99.1 Document Exhibit 99.1 THE BALDWIN GROUP ANNOUNCES SECOND QUARTER 2026 RESULTS — Second Quarter Total Revenue Growth of 30% to $492.9 Million — — Second Quarter Net Loss of $56.0 Million; Adjusted EBITDA (1) Growth of 37% to $116.7

$PLTRMed

Stocks Erase Early Gains as Alphabet and Software Companies Fall

US stocks gave back early gains as software and defense shares fell. Alphabet dropped over 6% after Google DeepMind VP Jumper said to be leaving for Anthropic. Defense names slid after Iran said it made “major progress” with the US on a peace deal. Rates: 10-year Treasury yield rose to 4.489% amid $211B in auctions. Semiconductors and AI stocks led gains; Palantir, Intuit, Oracle fell, while SOXX hit a record.

$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.